Press releases

Receive e-mail alerts

Internal link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
December 30, 2021 at 12:00 PM UTC
Internal link ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
December 16, 2021 at 12:00 PM UTC
Internal link ProQR Announces Highlights from Analyst Event
November 18, 2021 at 09:01 PM UTC
Internal link ProQR to Webcast Virtual Analyst Event on November 18
November 11, 2021 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in November and December
November 08, 2021 at 09:30 PM UTC
Internal link ProQR Announces Third Quarter 2021 Operating and Financial Results
November 04, 2021 at 11:00 AM UTC
Internal link ProQR Appoints Theresa Heggie as Chief Commercial Officer
October 04, 2021 at 12:00 PM UTC
Internal link ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform
September 08, 2021 at 08:15 PM UTC
Internal link ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
September 08, 2021 at 08:01 PM UTC
Internal link ProQR Announces Virtual Presentation at EURETINA 2021
September 06, 2021 at 08:15 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences
September 03, 2021 at 12:00 PM UTC
Internal link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference
August 11, 2021 at 08:30 PM UTC
Internal link ProQR Announces Second Quarter 2021 Operating and Financial Results
August 05, 2021 at 11:00 AM UTC
Internal link ProQR to Present at Upcoming JMP Securities Life Sciences Conference
June 10, 2021 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2021 Operating and Financial Results
May 06, 2021 at 11:00 AM UTC
Internal link ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target
May 04, 2021 at 11:00 AM UTC
Internal link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021
April 23, 2021 at 11:00 AM UTC
Internal link ProQR Announces Participation in Upcoming Kempen Life Sciences Conference
April 22, 2021 at 11:00 AM UTC
Internal link ProQR Announces Annual Meeting of Shareholders
April 20, 2021 at 11:00 AM UTC
Internal link ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10
April 13, 2021 at 08:15 PM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 05, 2021 at 08:15 PM UTC
Internal link ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021
April 02, 2021 at 08:15 PM UTC
Internal link ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares
March 31, 2021 at 02:25 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
March 30, 2021 at 08:05 PM UTC
Internal link ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
March 24, 2021 at 11:00 AM UTC

Press releases

Internal link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

Internal link ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

Internal link ProQR Announces Highlights from Analyst Event

Internal link ProQR to Webcast Virtual Analyst Event on November 18

Internal link ProQR Announces Upcoming Investor Conferences in November and December

Internal link ProQR Announces Third Quarter 2021 Operating and Financial Results

Internal link ProQR Appoints Theresa Heggie as Chief Commercial Officer

Internal link ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform

Internal link ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly

Internal link ProQR Announces Virtual Presentation at EURETINA 2021

Internal link ProQR Announces Upcoming Investor Conferences

Internal link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference

Internal link ProQR Announces Second Quarter 2021 Operating and Financial Results

Internal link ProQR to Present at Upcoming JMP Securities Life Sciences Conference

Internal link ProQR Announces First Quarter 2021 Operating and Financial Results

Internal link ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target

Internal link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021

Internal link ProQR Announces Participation in Upcoming Kempen Life Sciences Conference

Internal link ProQR Announces Annual Meeting of Shareholders

Internal link ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10

Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Internal link ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

Internal link ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares

Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Internal link ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials